Pharmacogenetics and psychopharmacology

Current Opinion in Pharmacology

Volumn 4, Issue 1, 2004, Pages 72-78

  Bondy, Brigitta ^a   Zill, Peter ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CARRIER PROTEIN; CLOZAPINE; DIAZEPAM; DRUG METABOLIZING ENZYME; ENZYME; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; HYPERFORIN; MEPHENYTOIN; MIRTAZAPINE; MOCLOBEMIDE; NEUROTRANSMITTER RECEPTOR; NICOTINE; OLANZAPINE; PROPRANOLOL; PSYCHOTROPIC AGENT; REBOXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZUCLOPENTHIXOL;

ARTICLE; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ENZYMATIC DEGRADATION; EXTRAPYRAMIDAL SYMPTOM; GENE EXPRESSION; GENE MUTATION; GENETIC CODE; GENETIC VARIABILITY; GENOME ANALYSIS; HEREDITY; HUMAN; HYPOTHESIS; INCIDENCE; MOOD DISORDER; NONHUMAN; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 0742271348     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2003.09.007     Document Type: Review

References (44)

1. Weinshilboum R. Inheritance and drug response N Engl J Med 348 2003 529-537
2. Lerer B. Macciardi F. Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions Int J Neuropsychopharmacol 5 2002 255-275
3. Johnson J.A. Lima J.J. Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges Pharmacogenetics 13 2003 525-534
4. Lindpaintner K. Pharmacogenetics and pharmacogenomics in drug discovery and development: an overview Clin Chem Lab Med 41 2003 398-410
5. Dahl M.L. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 41 2002 453-470
6. Poolsup N. Li Wan P.A. Knight T.L. Pharmacogenetics and psychopharmacotherapy J Clin Pharm Ther 25 2000 197-220
7. Oscarson M. Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine Clin Chem Lab Med 41 2003 573-580
8. Cichon S. Nothen M.M. Rietschel M. Propping P. Pharmacogenetics of schizophrenia Am J Med Genet 97 2000 98-106
9. Fang J. Gorrod J.W. Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs Cell Mol Neurobiol 19 1999 491-510
10. Lohmann P.L. Bagli M. Krauss H. Muller D.J. Schulze T.G. Fangerau H. Ludwig M. Barkow K. Held T. Heun R. et al. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients Pharmacopsychiatry 36 2003 73-78
11. Bertilsson L. Dahl M.L. Dalen P. Al Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs Br J Clin Pharmacol 53 2002 111-122
12. Scordo M.G. Spina E. Cytochrome P450 polymorphisms and response to antipsychotic therapy Pharmacogenomics 3 2002 201-218
13. Young L.T. Bakish D. Beaulieu S. The neurobiology of treatment response to antidepressants and mood stabilizing medications J Psychiatry Neurosci 27 2002 260-265
14. Basile V.S. Masellis M. Potkin S.G. Kennedy J.L. Pharmacogenomics in schizophrenia: the quest for individualized therapy Hum Mol Genet 11 2002 2517-2530
15. Mancama D. Arranz M.J. Kerwin R.W. Genetic predictors of therapeutic response to clozapine: current status of research CNS Drugs 16 2002 317-324
16. Reynolds G.P. Zhang Z. Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain Am J Psychiatry 160 2003 677-679
17. Malhotra A.K. Goldman D. Buchanan R.W. Rooney W. Clifton A. Kosmidis M.H. Breier A.Pickar D.The dopamine D-3 receptor (DRD3) Ser-9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response Mol Psychiatry 3 1998 72-75
18. Scharfetter J. Chaudhry H.R. Hornik K. Fuchs K. Sieghart W. Kasper S. Aschauer H.N. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients Eur Neuropsychopharmacol 10 1999 17-20
19. Masellis M. Basile V.S. Ozdemir V. Meltzer H.Y. Macciardi F.M. Kennedy J.L. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine Biol Psychiatry 47 2000 252-266
20. Seeman P. Vantol H.H.M. Dopamine receptor pharmacology Trends Pharmacol Sci 15 1994 264-270
21. Thompson J. Thomas N. Singleton A. Piggott M. Lloyd S. Perry E.K. Morris C.M. Perry R.H. Ferrier I.N. Court J.A. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele Pharmacogenetics 7 1997 479-484
22. Schäfer M. Rujescu D. Giegling I. Guntermann A. Erfurth A. Bondy B. Möller H. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D2 receptor gene Am J Psychiatry 158 2001 802-804
23. Heils A. Teufel A. Petri S. Stober G. Riederer P. Bengel D. Lesch K.P. Allelic variation of human serotonin transporter gene expression J Neurochem 66 1996 2621-2624
24. Serretti A. Lilli R. Smeraldi E. Pharmacogenetics in affective disorders Eur J Pharmacol 438 2002 117-128
25. Mancama D. Kerwin R.W. Role of pharmacogenomics in individualising treatment with SSRIs CNS Drugs 17 2003 143-151
26. Serretti A. Artioli P. Predicting response to lithium in mood disorders: role of genetic polymorphisms Am J Pharmacogenomics 3 2003 17-30
27. Ueno S. Genetic polymorphisms of serotonin and dopamine transporters in mental disorders J Med Invest 50 2003 25-31
28. Zill P. Baghai T.C. Zwanzger P. Schule C. Minov C. Behrens S. Rupprecht R. Moller H.J. Engel R. Bondy B. Association analysis of a polymorphism in the G-protein stimulatory alpha subunit in patients with major depression Am J Med Genet 114 2002 530-532
29. Siffert W. G-protein beta3 subunit 825T allele and hypertension Curr Hypertens Rep 5 2003 47-53
30. Zill P. Baghai T.C. Zwanzger P. Schule C. Minov C. Riedel M. Neumeier K. Rupprecht R. Bondy B. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment Neuroreport 11 2000 1893-1897
31. Serretti A. Lorenzi C. Cusin C. Zanardi R. Lattuada E. Rossini D. Lilli R. Pirovano A. Catalano M. Smeraldi E. SSRIs antidepressant activity is influenced by G beta 3 variants Eur Neuropsychopharmacol 13 2003 117-122
32. Zill P. Baghai T.C. Engel R. Zwanzger P. Schule C. Minov C. Behrens S. Bottlender R. Jager M. Rupprecht R. Moller H.J. Ackenheil M. Bondy B. Beta-1-adrenergic receptor gene in major depression: Influence on antidepressant treatment response Am J Med Genet 120B 2003 85-89
33. Moskowitz D.W. Is angiotensin I-converting enzyme a 'master' disease gene? Diabetes Technol Ther 4 2002 683-711
34. Rigat B. Hubert C. Alhenc G.F. Cambien F. Corvol P. Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels J Clin Invest 4 1990 1346
35. Arinami T. Li L. Mitsushio H. Itokawa M. Hamaguchi H. Toru M. An insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders Biol Psychiatry 40 1996 1122-1127
36. Baghai T. Schüle C. Zwanzger P. Minov C. Schwarz J. de Jonge S. Rupprecht R. Bondy B. Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders Mol Psychiatry 6 2001 258-259
37. Shilling P.D. Kelsoe J.R. Functional genomics approaches to understanding brain disorders Pharmacogenomics 3 2002 31-45
38. Castren E. Kontkanen O. Functional genomics in neuropsychiatric disorders and in neuropharmacology Expert Opin Ther Targets 6 2002 363-374
39. Chong V.Z. Young L.T. Mishra R.K. cDNA array reveals differential gene expression following chronic neuroleptic administration: implications of synapsin II in haloperidol treatment J Neurochem 82 2002 1533-1539
40. Landgrebe J. Welzl G. Metz T. van Gaalen M.M. Ropers H. Wurst W. Holsboer F. Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling J Psychiatr Res 36 2002 119-129
41. Arranz M.J. Munro J. Sham P. Kirov G. Murray R.M. Collier D.A. Kerwin R.W. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response Schizophr Res 32 1998 93-99
42. Basile V.S. Masellis M. De Luca V. Meltzer H.Y. Kennedy J.L. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain Lancet 360 2002 1790-1791
43. Pickar D. Rubinow K. Pharmacogenomics of psychiatric disorders Trends Pharmacol Sci 22 2001 2-83
44. Cusin C. Serretti A. Zanardi R. Lattuada E. Rossini D. Lilli R. Lorenzi C. Smeraldi E. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity Int J Neuropsychopharmacol 5 2002 27-35